WNT3A and metabolic syndrome: They showed that these two miRNAs promote endoplasmic reticulum-mediated apoptosis through the Wnt3a/β-catenin pathway [48], suggesting that activating these miRNAs could potentially serve as novel therapies for treating obesity and metabolic syndrome-related diseases.